NTI Drugs Remain Big Issue

Focus

WASHINGTON -- The generic drug industry is recruiting support from various health care organizations in the controversy centering or drug substitution and Narrow Therapeutic Index (NTI) drugs.

At last month's meeting of the National Association of Pharmaceutical Manufacturers (NAPM) a panel endorsed the interchangeability of all generic drug products that had been approved by the Food and Drug Administration (FDA).

NAPM and other generic trade groups have charged that brand name companies, in an effort to postpone market entry of generic drug products that have already been approved by the FDA, have lobbied state legislatures across the country to …